PRNewsWire
14 Jul 2026, 11:45 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
4 claims · each scored for market impact
Valion Bio is pursuing government procurement and stockpiling agreements for Entolimod as a medical countermeasure for Acute Radiation Syndrome (ARS) with BARDA, NIAID, AFRRI, and the DoW. — Securing government contracts for strategic stockpiles typically provides significant, non-dilutive revenue and validates the product's utility.
+0.60The company has achieved a 200-fold manufacturing scale-up for its Entolimod platform through its subsidiary, Velocity Bioworks®. — Scaling manufacturing reduces operational risk and is a prerequisite for commercialization and government procurement.
+0.40Valion Bio is engaging with Ukraine's Ministry of Health regarding the potential inclusion of Entolimod in Ukraine's national strategic reserves. — International expansion into strategic reserves opens new revenue streams and provides real-world utility data.
+0.30Continue reading
6 related stories
Top 1 mover · tap to explore
The company is planning an expansion of the Entolimod platform into oncology supportive care. — Diversifying the pipeline into oncology increases the total addressable market beyond niche government biodefense.
+0.20Which stocks this story touches
The company is reporting positive strategic progress in government engagement, manufacturing scale-up, and expansion into oncology supportive care.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
PRNewsWire
16h ago
